Christopher Barden, Treventis CEO

Take­da joins forces with small pri­vate biotech for pre­clin­i­cal Alzheimer's re­search

Take­da is wad­ing deep­er in­to Alzheimer’s dis­ease re­search with a new pre­clin­i­cal col­lab­o­ra­tion an­nounced Tues­day.

The com­pa­ny will work with Treven­tis, a lit­tle-known pri­vate biotech from Toron­to, on a small mol­e­cule pro­gram tar­get­ing the tau pro­tein. Treven­tis CEO Christo­pher Bar­den tells End­points News the biotech is still work­ing on se­lect­ing which drug can­di­date to move for­ward and will use Take­da’s help to make that choice. Take­da can then op­tion it in­to fur­ther pre­clin­i­cal, and po­ten­tial­ly clin­i­cal, stud­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.